Isomorphic Labs
@IsomorphicLabs • 57,789 subscribers
Solve all disease. Developing and applying frontier AI to unlock deeper scientific insights, faster breakthroughs, and life-changing medicines.
Shorts
Videos
Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:
Isomorphic Labs272,250 görüntüleme • 1 ay önce
We recently released a technical report highlighting how Isomorphic Labs’ drug design engine is achieving a step change in how we model complex biological mechanisms, consistently outperforming industry benchmarks. Read our blog to discover how we’re bridging the gap between structure prediction and rational drug design. You can find the link in the comments.
Isomorphic Labs125,087 görüntüleme • 3 ay önce
“One of the great things about Iso is how interdisciplinary everyone is, people come from so many different backgrounds.” We spoke with Bilal Khan, Software Engineer at Isomorphic Labs, about our unique, collaborative culture and frontier AI built to tackle the world's most complex problems. Watch the video and head to the comments to explore our current roles.
Isomorphic Labs19,571 görüntüleme • 3 ay önce
“Some of these research problems we’ve been going after really are holy grail predictive problems for drug design - and we’ve made some incredible breakthroughs there, which have really stunned our chemists.” On Sequoia Capital’s Training Data podcast, our Chief AI Officer Max Jaderberg talks about the scale of AI drug discovery and its potential to transform how we design new medicines. Listen to the full podcast at the link below:
Isomorphic Labs12,294 görüntüleme • 1 yıl önce
Daha fazla içerik yok.